Quick Answer
Acrivon Therapeutics, Inc. reported Stockholders Equity of $112.52 million for fiscal year 2025.
Acrivon Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $112.52M | -36.4% |
| 2024 | $176.79M | +45.9% |
| 2023 | $121.19M | -28.9% |
| 2022 | $170.47M | +816.0% |
| 2021 | -$23.81M | -183.0% |
| 2020 | -$8.41M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $128.60M | -34.7% | -10.1% |
| June 30, 2025 | $143.04M | -33.8% | -10.8% |
| March 31, 2025 | $160.39M | +48.5% | -9.3% |
| December 31, 2024 | $176.79M | +45.9% | -10.2% |
| September 30, 2024 | $196.89M | +42.5% | -8.9% |
| June 30, 2024 | $216.06M | +44.8% | +100.1% |
| March 31, 2024 | $107.98M | -32.7% | -10.9% |
| December 31, 2023 | $121.19M | -28.9% | -12.3% |
- Acrivon Therapeutics, Inc. showed a decrease of -36.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Acrivon Therapeutics, Inc.’s stockholders equity has grown by 1437.4% (from -$8.41 million to $112.52 million).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: